IPO Year: 2015
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2025 | Overweight | Cantor Fitzgerald | |
| 6/2/2025 | $15.00 | Buy | H.C. Wainwright |
| 3/25/2025 | $36.00 | Buy | Stifel |
| 3/25/2025 | $23.00 | Buy | Jefferies |
| 2/28/2025 | $48.00 | Overweight | Piper Sandler |
| 2/21/2025 | $18.00 | Outperform | Wedbush |
| 12/19/2024 | $40.00 | Buy | BTIG Research |
| 10/24/2024 | Neutral | H.C. Wainwright | |
| 4/16/2024 | $35.00 | Perform → Outperform | Oppenheimer |
| 3/3/2022 | $5.00 → $0.75 | Buy → Hold | Jefferies |
SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
10-Q - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
Live Leadership Updates
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. "We are thrilled to have Mittie join and grow our leadership team at an exciting time as we prepare to initiate our Phase 2 LOTUS Trial in patients with hidradenitis suppurativa. Mittie brings to Avalo a strong combination of drug development experience through all stages of development and exceptional expertise in immunology, rheumatology and dermatology," said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. "Her leadership guided by her robust experience will be invaluable to th
WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. "We are delighted to have Paul join and grow our leadership team at an exciting time at Avalo following our acquisition and private placement earlier this year," said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. "Paul's deep industry experience will immediately enhance our strategic and legal competencies. Furthermore, we expect his appointment will augment our ability to create and protect value as well as minimize risk as we progress AVTX-009 in hidradenitis suppurativa and plan for the
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Cantor Fitzgerald initiated coverage of Avalo Therapeutics with a rating of Overweight
H.C. Wainwright resumed coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $15.00
Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00
Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00
Piper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00
Wedbush initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $18.00
BTIG Research initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $40.00
H.C. Wainwright initiated coverage of Avalo Therapeutics with a rating of Neutral
Oppenheimer upgraded Avalo Therapeutics from Perform to Outperform and set a new price target of $35.00
Jefferies downgraded Avalo Therapeutics from Buy to Hold and set a new price target of $0.75 from $5.00 previously
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
Fastest customizable press release news feed in the world
Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2025. "The team has made tremendous progress on the execution of the Phase 2 LOTUS trial in
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences: HCW Annual Inflammation & Immunology Virtual ConferenceFireside ChatJune 30, 2025, at 11:00 am ET BTIG Virtual Biotechnology Conference 20251x1sJuly 29-30, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Th
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New YorkFireside ChatJune 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New YorkPanelist: "Dermatology: AA, HS, PSO"June 25, 2025, at 10am ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available f
Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025. "We have made considerable progress in our Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with site activations, screenings
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,
WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Health Care Conference, BostonCorporate PresentationMarch 3, 2025, at 3:10 pm ET Leerink Partners Global Healthcare Conference, Miami 1x1 and small group meetings March 12, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available fo
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET. Live webcast and replay can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinic
This live feed shows all institutional transactions in real time.
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)